Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Stablecoin Development Corp incurred convertible notes of $3.3 million aggregate principal amount with existing accredited institutional investors maturing eighteen (18) months from the date of issuance.
- Instrument
- convertible notes
- Principal
- $3.3 million aggregate principal amount
- Counterparty
- existing accredited institutional investors
- Maturity
- eighteen (18) months from the date of issuance
- Event
- incurrence
Exact text from the filing
of (i) $3.3 million aggregate principal amount of original issue discount senior secured convertible debentures due eighteen (18) months from the date of issuance
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.98
Stablecoin Development Corp entered into Securities Purchase Agreement with existing accredited institutional investors valued at $3.3 million aggregate principal amount (effective 2023-04-27).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- existing accredited institutional investors
- Value
- $3.3 million aggregate principal amount
- Effective
- 2023-04-27
Exact text from the filing
On April 27, 2023, NovaBay Pharmaceuticals, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with existing accredited institutional investors (the “Purchasers”) of the Company that provides for the issuance and sale in a private placement (the “Private Placement”) of (i) $3.3 million aggregate principal amount of original issue discount senior secured convertible debentures due eighteen (18) months from the date of issuance (the “Debentures”)
View on SEC.gov